EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study

Andre M Small iD, Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich iD, Bruce Hug iD, Sanobar Parkar, Shih-Ann Chen iD, Shaun G Goodman iD, Boyoung Joung iD, Róbert G Kiss, Wojciech Wojakowski und 4 weitere

Blood · 06.08.2026 · 148 (6) · 789-792

DOI: 10.1182/blood.2026033829 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Blood, erschienen am 06.08.2026. Verfasst von Andre M Small und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Hemorrhage, Anticoagulants, Factor XI, Atrial Fibrillation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This prespecified AZALEA-TIMI 71 analysis showed that prior oral anticoagulation (OAC) experience indicates bleeding risk in atrial fibrillation. The factor XI inhibitor abelacimab reduced bleeding regardless of prior OAC experience, with potentially greater absolute benefit among OAC-naïve patients. This trial was registered at www.ClinicalTrials.gov as NCT04755283.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageAnticoagulantsFactor XIAtrial FibrillationAntibodies, Monoclonal, HumanizedHumansFemaleMaleAgedRisk FactorsRecombinant ProteinsFactor Xa

Substanzen

AnticoagulantsFactor XIAntibodies, Monoclonal, HumanizedPRT064445Recombinant ProteinsFactor Xa

Autor:innen und Institutionen

  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
  • Anthos Therapeutics, Inc, Cambridge, MA.
  • Heart Rhythm Center, Cardiovascular Center, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Institute of Clinical Medicine and Cardiovascular Research Institute, National Yang Ming Chiao Tung, University, Taipei, Taiwan.

ORCID-Profile: Andre M Small, Erica L Goodrich, Bruce Hug, Shih-Ann Chen, Shaun G Goodman, Boyoung Joung, Marc S Sabatine

Zitieren

APA

Small, A. M., Patel, S. M., Giugliano, R. P., Morrow, D. A., Goodrich, E. L., Hug, B., Parkar, S., Chen, S. A., Goodman, S. G., Joung, B., Kiss, R. G., Wojakowski, W., Weitz, J. I., Bloomfield, D., Sabatine, M. S., & Ruff, C. T. (2026). Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study. Blood, 148(6), 789-792. https://doi.org/10.1182/blood.2026033829

Vancouver

Small AM, Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Hug B, et al. Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study. Blood. 2026;148(6):789-792. doi:10.1182/blood.2026033829

BibTeX
@article{Small2026,
  author = {Small, Andre M and Patel, Siddharth M and Giugliano, Robert P and Morrow, David A and Goodrich, Erica L and Hug, Bruce and Parkar, Sanobar and Chen, Shih-Ann and Goodman, Shaun G and Joung, Boyoung and Kiss, Róbert G and Wojakowski, Wojciech and Weitz, Jeffrey I and Bloomfield, Dan and Sabatine, Marc S and Ruff, Christian T},
  title = {Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study},
  journal = {Blood},
  year = {2026},
  volume = {148},
  number = {6},
  pages = {789--792},
  doi = {10.1182/blood.2026033829}
}
Kostenlos starten →